n 0437, (-)-isomer has been researched along with Daytime Sleepiness in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albanese, M; Liguori, C; Mercuri, NB; Olivola, E; Pierantozzi, M; Stefani, A | 1 |
| Perez-Lloret, S; Rascol, O | 1 |
| Chitnis, S; Dewey, RB; Jaffery, M | 1 |
1 review(s) available for n 0437, (-)-isomer and Daytime Sleepiness
| Article | Year |
|---|---|
Rotigotine transdermal delivery for the treatment of Parkinson's disease.
Topics: Administration, Cutaneous; Antiparkinson Agents; Controlled Clinical Trials as Topic; Disorders of Excessive Somnolence; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Nausea; Parkinson Disease; PubMed; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome | 2009 |
2 trial(s) available for n 0437, (-)-isomer and Daytime Sleepiness
| Article | Year |
|---|---|
Daytime sleepiness may be an independent symptom unrelated to sleep quality in Parkinson's disease.
Topics: Aged; Disorders of Excessive Somnolence; Dopamine Agonists; Female; Follow-Up Studies; Humans; Male; Middle Aged; Parkinson Disease; Polysomnography; Sleep Wake Disorders; Tetrahydronaphthalenes; Thiophenes | 2019 |
Outcomes from switching from rotigotine patch to alternate therapies in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Disorders of Excessive Somnolence; Dopamine Agonists; Female; Follow-Up Studies; Humans; Male; Middle Aged; Parkinson Disease; Prospective Studies; Tetrahydronaphthalenes; Thiophenes | 2012 |